CD274 and neoplasm: Based on the results of the phase III KEYNOTE-024 trial, patients treated with pembrolizumab showed much longer progression-free survival (PFS) and overall survival (OS) than those treated with platinum-based chemotherapy, and patients of both groups had at least 50% PD-L1 expression on their tumor cells 3.